専門分野

• ゲノム創薬科学
• 内科学

担当科目

• 3年 分子生物学
• 4年 分子生物学実習、臨床医学各論

メッセージ

• 人体の生理学を十分に理解し、なぜ病気になるのかを分かりやすく授業する事を心掛けています。また、私たちの研究室ではゲノム創薬科学にもとづき、疾患発症のメカニズムを分子レベルで理解する事により病気の新しい治療法の確立を目指しています。

オフィスアワー

• 月曜日：13:00-14:30
• 火曜日：13:00-14:30

学歴

• 2007-
• 姫路獨協大学薬学部 教授
• 2002-2007
• 大阪大学医学部 助手
• 1997-2002
• 慶應義塾大学医学部 助手
• 1991-1997
• 慶應義塾大学医学部 内科

学位

• 1999年 医学博士

所属学会

• 日本内科学会
• 日本循環器学会

論文・解説

原著論文

• Hayashi K, Shibata K, Morita T, Iwasaki K, Watanabe M, Sobue K. Insulin Receptor Substrate-1/SHP-2 Interaction, a Phenotype-dependent Switching Machinery of Insulin-like Growth Factor-I Signaling in Vascular Smooth Muscle Cells.J Biol Chem. 279: 40807-40818, 2004.
• Brunner M, Kodirov SA, Mitchell GF, Buckett PD, Shibata K, Folco EJ, Baker L, Salama G, Chan DP, Zhou J, Koren G.In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype.
  Am J Physiol Heart Circ Physiol. 285: H194-203, 2003.
• Shibata K, Katsuma S, Koshimizu T, Shinoura H, Hirasawa A, Tanoue A, Tsujimoto G. 1-Adrenergic receptor subtypes differentially control the cell cycle of transfected CHO cells through a cAMP- dependent mechanism involving p27Kip1. J Biol Chem. 278: 672-678, 2003.
• Shinoura H, Shibata K, Hirasawa A, Tanoue A, Hashimoto K, Tsujimoto G. Key amino acids for differential coupling of 1-adrenergic receptor subtypes to Gs. Biochem. Biophys. Res. Commun. 299: 142-147, 2002.
• Homma N, Hirasawa A, Shibata K, Hashimoto K, Tsujimoto G. Both 1A-and 1B-adrenergic receptor subtypes couple to the transient outward current (ITO) in rat ventricular myocytes. Br. J. Pharamacol. 129: 1113-1120, 2000.
• Takei R, Ikegaki I, Shibata K, Tsujimoto G, AsanoT.Naftopidil, a novel 1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human 1-adrenoceptors. Jpn. J. Pharmacol. 79: 447-454, 1999.
• Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G. Effects of Quinidine and Verapamil on human cardiovascular 1- adrenoceoptors. Circulation 97: 1227-1230, 1998.
• Take H, Shibata K, Awaji T, Hirasawa A, Ikegaki I, Asano T, Takada T, Tsujimoto G. Vasacular 1-adrenoceptor subtype selectivity and 1-blocker-induced orthostatic hypotension. Jpn. J. Pharmacol. 77: 61-70, 1998.
• Shibata K, Hirasawa A, Moriyama N, Kawabe K, Ogawa S, Tsujimoto G. 1a-Adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. Br. J. Pharmacol. 118: 1403-1408, 1996.
• Hirasawa A, Tsumaya K, Awaji T, Shibata K, Homma N, Shinomiya T, Tsujimoto G. Flow cytometry analysis of 1- adrenoceptor subtypes. FEBS Letters 386: 141-148, 1996.
• Obika K, Shibata K, Horie K, Foglar R, Kimura K, Tsujimoto G. NS-49, a novel 1a-adrenoceptor-selective agonist: Characterization using recombinant human 1-adrenoceptors. Eur. J. Pharmacol. (Mol. Pharmacol. section) 291: 327-334, 1995.
• Shibata K, Foglar R, Horie K, Obika K, Sakamoto A, Ogawa S, Tsujimoto G. KMD-3213, a novel, potent 1a-adrenoceptor- selective antagonist: Characterization using recombinant human 1- adrenoceptors and native tissues. Mol. Pharmacol. 48: 250-258, 1995.
• Hirasawa A, Shibata K, Horie K, Takei Y, Obika K, Tanaka T, Muramoto N, Takagaki K, Yano J, Tsujimoto G. Cloning, functional expression and tissue distribution of human 1C- adrenoceptor splice variants. FEBS Letters 363: 256-260, 1995.
• Ono K, Eto K, Sakamoto A, Masaki T, Shibata K, Sada T, Hashimoto K, Tsujimoto G. A negative chronotropic effect of endothelin-1 mediated through ETA receptor in guinea pig atria. Circ. Res. 76: 284-292, 1995.
• Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur. J. Pharmacol. (Mol. Pharmacol. Section) 288: 201-207, 1995.
• Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem. Biophys. Res. Commun. 203: 72-79, 1994.